Compare Stocks: GALT, SVRA, KURA, and SANA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GALT Galectin Therapeutics	$3.91 +0.3%	$3.85	$2.03 ▼ $7.13	$257.50M	0.38	311,404 shs	243,553 shs
KURA Kura Oncology	$11.39 -1.6%	$11.23	$7.36 ▼ $13.90	$1.01B	0.44	2.25 million shs	2.12 million shs
SANA Sana Biotechnology	$3.13 +1.3%	$3.59	$2.61 ▼ $6.55	$937M	2.12	2.92 million shs	3.28 million shs
SVRA Savara	$5.30 -0.4%	$5.58	$3.34 ▼ $7.01	$1.09B	0.25	1.45 million shs	1.06 million shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GALT Galectin Therapeutics	0.00%	-15.18%	+10.76%	+46.44%	-21.80%
KURA Kura Oncology	0.00%	-14.04%	+12.88%	+25.86%	+39.41%
SANA Sana Biotechnology	0.00%	-18.70%	-14.71%	+16.79%	+7.56%
SVRA Savara	0.00%	-1.30%	+0.57%	+0.76%	+38.38%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GALT Galectin Therapeutics	$3.91 +0.3%	$3.85	$2.03 ▼ $7.13	$257.50M	0.38	311,404 shs	243,553 shs
KURA Kura Oncology	$11.39 -1.6%	$11.23	$7.36 ▼ $13.90	$1.01B	0.44	2.25 million shs	2.12 million shs
SANA Sana Biotechnology	$3.13 +1.3%	$3.59	$2.61 ▼ $6.55	$937M	2.12	2.92 million shs	3.28 million shs
SVRA Savara	$5.30 -0.4%	$5.58	$3.34 ▼ $7.01	$1.09B	0.25	1.45 million shs	1.06 million shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GALT Galectin Therapeutics	0.00%	-15.18%	+10.76%	+46.44%	-21.80%
KURA Kura Oncology	0.00%	-14.04%	+12.88%	+25.86%	+39.41%
SANA Sana Biotechnology	0.00%	-18.70%	-14.71%	+16.79%	+7.56%
SVRA Savara	0.00%	-1.30%	+0.57%	+0.76%	+38.38%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
GALT Galectin Therapeutics	2.00	Hold	$11.00	181.33% Upside
KURA Kura Oncology	2.75	Moderate Buy	$25.40	123.00% Upside
SANA Sana Biotechnology	2.80	Moderate Buy	$9.33	198.19% Upside
SVRA Savara	2.88	Moderate Buy	$10.00	88.68% Upside

Current Analyst Ratings Breakdown

Latest GALT, SVRA, KURA, and SANA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/24/2026	KURA Kura Oncology	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$24.00
8/24/2026	KURA Kura Oncology	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$24.00
8/24/2026	KURA Kura Oncology	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform
8/24/2026	KURA Kura Oncology	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform	$24.00
8/24/2026	SANA Sana Biotechnology	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
8/14/2026	SANA Sana Biotechnology	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$7.00 ➝ $6.00
8/13/2026	KURA Kura Oncology	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$36.00 ➝ $38.00
8/11/2026	GALT Galectin Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
7/28/2026	KURA Kura Oncology	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$36.00
7/23/2026	SANA Sana Biotechnology	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/17/2026	KURA Kura Oncology	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)

(Data available from 9/13/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
GALT Galectin Therapeutics	N/A	N/A	N/A	N/A	($1.99) per share	N/A
KURA Kura Oncology	$67.48M	15.02	N/A	N/A	$2.00 per share	5.70
SANA Sana Biotechnology	N/A	N/A	N/A	N/A	$0.60 per share	N/A
SVRA Savara	N/A	N/A	N/A	N/A	$1.00 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
GALT Galectin Therapeutics	-$30.84M	-$0.43	N/A	N/A	N/A	N/A	N/A	-176.83%	11/13/2026 (Estimated)
KURA Kura Oncology	-$278.67M	-$3.37	N/A	N/A	N/A	-384.30%	-207.18%	-45.17%	11/3/2026 (Estimated)
SANA Sana Biotechnology	-$244.17M	-$0.76	N/A	N/A	N/A	N/A	-103.02%	-39.16%	11/5/2026 (Estimated)
SVRA Savara	-$118.84M	-$0.58	N/A	N/A	N/A	N/A	-90.28%	-68.95%	11/11/2026 (Estimated)

Latest GALT, SVRA, KURA, and SANA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2026	Q2 2026	GALT Galectin Therapeutics	-$0.09	-$0.14	-$0.05	-$0.14	N/A	N/A
8/12/2026	Q2 2026	KURA Kura Oncology	-$0.8773	-$0.77	+$0.1073	-$0.77	$20.16 million	$20.87 million
8/11/2026	Q2 2026	SVRA Savara	-$0.1413	-$0.16	-$0.0188	-$0.16	$2.00 million	N/A
8/10/2026	Q2 2026	SANA Sana Biotechnology	-$0.1469	-$0.13	+$0.0169	-$0.22	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
GALT Galectin Therapeutics	N/A	N/A	N/A	N/A	N/A
KURA Kura Oncology	N/A	N/A	N/A	N/A	N/A
SANA Sana Biotechnology	N/A	N/A	N/A	N/A	N/A
SVRA Savara	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
GALT Galectin Therapeutics	N/A	0.10	0.10
KURA Kura Oncology	0.12	4.73	4.71
SANA Sana Biotechnology	N/A	1.38	1.38
SVRA Savara	0.21	10.13	10.13

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
GALT Galectin Therapeutics	11.68%
KURA Kura Oncology	N/A
SANA Sana Biotechnology	88.23%
SVRA Savara	87.93%

Insider Ownership

Company	Insider Ownership
GALT Galectin Therapeutics	52.60%
KURA Kura Oncology	7.60%
SANA Sana Biotechnology	25.40%
SVRA Savara	5.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
GALT Galectin Therapeutics	9	65.86 million	31.22 million	Optionable
KURA Kura Oncology	260	88.96 million	82.20 million	Optionable
SANA Sana Biotechnology	142	299.36 million	223.32 million	Optionable
SVRA Savara	70	205.46 million	194.57 million	Optionable

GALT, SVRA, KURA, and SANA Headlines

Recent News About These Companies

Bank of New York Mellon Corp Acquires New Shares in Savara Inc. $SVRA

September 8, 2026 | marketbeat.com

Jupiter Topco LLC Invests $2.88 Million in Savara Inc. $SVRA

September 3, 2026 | marketbeat.com

BlackRock Inc. Takes $76.97 Million Position in Savara Inc. $SVRA

August 31, 2026 | marketbeat.com

6,976,810 Shares in Savara Inc. $SVRA Purchased by Nantahala Capital Management LLC

August 29, 2026 | marketbeat.com

Algert Global LLC Purchases 464,645 Shares of Savara Inc. $SVRA

August 27, 2026 | marketbeat.com

ADAR1 Capital Management LLC Purchases New Shares in Savara Inc. $SVRA

August 26, 2026 | marketbeat.com

Spruce Street Capital LP Acquires New Shares in Savara Inc. $SVRA

August 25, 2026 | marketbeat.com

Deutsche Bank AG Makes New $5.33 Million Investment in Savara Inc. $SVRA

August 25, 2026 | marketbeat.com

Savara Announces Encore Presentations of Results from the Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis ...

August 24, 2026 | uk.finance.yahoo.com

Savara Announces Encore Presentations of Results from the Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (APAP) at the European Respiratory Society (ERS) Congress 2026

August 24, 2026 | businesswire.com

Savara Inc. (NASDAQ:SVRA) Receives Average Rating of "Moderate Buy" from Analysts

August 24, 2026 | marketbeat.com

Savara Inc. (SVRA) Latest Press Releases & Corporate News - Yahoo Finance

August 20, 2026 | finance.yahoo.com

Walleye Capital LLC Invests $1.53 Million in Savara Inc. $SVRA

August 15, 2026 | marketbeat.com

Savara (NASDAQ:SVRA) Stock Rating Lowered by Wall Street Zen

August 15, 2026 | marketbeat.com

HC Wainwright Brokers Lower Earnings Estimates for Savara

August 14, 2026 | marketbeat.com

Savara Reports Second Quarter 2026 Financial Results and Provides Business Update

August 11, 2026 | caledonianrecord.comC

Savara: High Potential Binary Bet Cruising To PDUFA After 3 Month Speed Bump

August 5, 2026 | seekingalpha.com

Savara (SVRA) Gets a Buy from Piper Sandler

July 24, 2026 | theglobeandmail.com

Here's Why You Should Add Savara Stock to Your Portfolio Now

July 22, 2026 | zacks.com

What Savara Investors Should Know About This 580,187-Option Exercise and FDA Timeline

June 27, 2026 | fool.com

What Is Driving Attention Toward Savara’s Rare Disease Strategy?

June 15, 2026 | kalkinemedia.comK

New MarketBeat Followers Over Time

Media Sentiment Over Time

GALT, SVRA, KURA, and SANA Company Descriptions

Galectin Therapeutics NASDAQ:GALT

$3.91 +0.01 (+0.26%)

As of 09/11/2026 04:00 PM Eastern

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.

Kura Oncology NASDAQ:KURA

$11.39 -0.18 (-1.56%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$11.45 +0.06 (+0.53%)

As of 09/11/2026 07:40 PM Eastern

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification. The company was founded in 2014 and is headquartered in San Diego, California.

Sana Biotechnology NASDAQ:SANA

$3.13 +0.04 (+1.29%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$3.15 +0.02 (+0.64%)

As of 09/11/2026 07:56 PM Eastern

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others. The company's product candidates include SC291 that is used as allogeneic cell therapies for hematologic malignancies; ARDENT for a potential treatment for non-Hodgkin's lymphoma, and chronic lymphoblastic leukemia; GLEAM, to treat multiple autoimmune disorders that involve production of autoimmune antibodies, including lupus nephritis, extrarenal lupus, antineutrophil cytoplasmic antibody -associated vasculitis, and others. It is developing SC262 to treat patients with relapsed and/or refractory B-cell malignancies; SC255 for multiple myeloma treatment; SC379, a therapy for patients with certain central nervous system disorders healthy allogeneic glial progenitor cells; SC451, a product candidate to treat diabetes, with an initial focus on type 1 diabetes mellitus; and UP421 that reduces long-term exogenous insulin dependence. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.

Savara NASDAQ:SVRA

$5.30 -0.02 (-0.38%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$5.38 +0.08 (+1.53%)

As of 09/11/2026 07:37 PM Eastern

Savara Inc., formerly Mast Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients. Molgradex is an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor. It is developing Molgradex for the treatment of autoimmune pulmonary alveolar proteinosis, a rare lung disease. AIR001 is a sodium nitrite solution for inhalation via nebulization. AIR001 is in Phase II clinical development for the treatment of heart failure with preserved ejection fraction, also known as diastolic heart failure or heart failure with preserved systolic function.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest GALT, SVRA, KURA, and SANA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest GALT, SVRA, KURA, and SANA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

GALT, SVRA, KURA, and SANA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

GALT, SVRA, KURA, and SANA Company Descriptions

Galectin Therapeutics NASDAQ:GALT

Kura Oncology NASDAQ:KURA

Sana Biotechnology NASDAQ:SANA

Savara NASDAQ:SVRA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest GALT, SVRA, KURA, and SANA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest GALT, SVRA, KURA, and SANA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

GALT, SVRA, KURA, and SANA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

GALT, SVRA, KURA, and SANA Company Descriptions

Galectin Therapeutics NASDAQ:GALT

Kura Oncology NASDAQ:KURA

Sana Biotechnology NASDAQ:SANA

Savara NASDAQ:SVRA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools